SERPINE1 and disease of the tendon: In this work, we propose the use of this platform of LPNs for developinga dual therapeutic approach targeting macrophages in tendinopathy.The optimized LPNs are loaded with a relevant anti-inflammatory smallmolecule drug, i.e., budesonide, and a relevant siRNA against thepro-fibrotic Serpine1 gene, which encodes for plasminogenactivator inhibitor 1 (PAI-1).